Seeking Alpha

Auxilium Pharmaceuticals (AUXL +0.3%) and strategic partner BioSpecifics (BSTC +1.3%) both move...

Auxilium Pharmaceuticals (AUXL +0.3%) and strategic partner BioSpecifics (BSTC +1.3%) both move up after The Journal of Urology publishes its Impress Study, a Phase 3 trial of Xiaflex for the treatment of Peyronie's disease, which is an excess of inelastic collagen causing penile curvature deformity. AUXL previously announced positive top-line efficacy and safety results of the studies' co-primary endpoints, and based on the new results, has submitted a supplemental Biologics License Application (sBLA) to the FDA.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs